Universitat De Les Illes Balears

Other

Pilar Sanchis Cortes

Bernat Isern Amengual

Joan Perello Bestard

Antonia Costa Bauza

Rafael M Prieto Almirall

Felix Grases Freixedas

Joan Perelló Bestard

Antonia Costa-Bauza

Rafael Mara Prieto Almirall

Ramon Garcia Gonzalez

Antonia Costa-bauzá

Rafael Mará Prieto Almirall

Ramón GARCÍA GONZÁLEZ

The invention relates to a fixed-dose association of phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.

Fixed-dose association of phytate and zinc

The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.

The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture of functional foods, dietetic supplements, vitamin supplements, nutritional supplements, food supplements, or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.

Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention of osteoporosis

Growing community of inventors

Palma De Mallorca, Spain

Pilar Sanchis Cortes